Enclomiphene Citrate Cost in Idaho 2026

What Is Enclomiphene Citrate and Why Is It Prescribed?

Enclomiphene citrate is the trans-isomer of clomiphene, an estrogen-receptor antagonist that acts at the hypothalamus to raise LH and FSH, thereby stimulating endogenous testosterone production. Because it preserves or increases sperm production rather than suppressing it, clinicians prefer it over exogenous testosterone therapy in men who want to maintain fertility. The compound is prescribed off-label in the United States for secondary (hypogonadotropic) hypogonadism, a condition in which low testosterone results from insufficient pituitary signaling rather than primary testicular failure.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism recommends confirming the diagnosis with two morning total testosterone measurements below 300 ng/dL alongside signs and symptoms before initiating any therapy [1]. Enclomiphene is not mentioned by name in that guideline because it lacked FDA approval at the time, but the guideline explicitly notes that "clomiphene citrate has been used off-label to stimulate endogenous testosterone production" as a category of treatment [1].

Kim et al. (BJU Int, 2016, N=75) demonstrated that enclomiphene citrate normalized serum testosterone in approximately 75% of men with secondary hypogonadism after 3 months of once-daily dosing, while simultaneously preserving sperm concentration [2]. That finding drives much of current prescribing interest. A separate phase III comparison published via the FDA advisory record showed that 25 mg enclomiphene daily raised mean total testosterone from roughly 230 ng/dL at baseline to above 400 ng/dL at week 12, meeting the prespecified primary endpoint [3].

Understanding what the drug does matters for Idaho cost planning because its off-label status is the single largest driver of insurance exclusions and Medicaid non-coverage across the state.

Enclomiphene Citrate Pricing in Idaho: The Full Breakdown

Cash prices in Idaho vary by source, dose, and pharmacy type. Compounded enclomiphene from a licensed 503A pharmacy costs approximately $90 per month for a standard 25 mg daily supply. Retail or branded preparations at chain pharmacies range from $150 to $250 per month. No Idaho pharmacy currently lists a manufacturer coupon that reduces the retail price to zero; discount aggregators such as GoodRx can reduce the retail price by 20 to 40% at participating locations, bringing a 30-day supply to roughly $110 to $180 depending on dose and outlet.

The 503A compounding route offers the lowest out-of-pocket cost for most Idaho patients. Under federal law, 503A pharmacies compound patient-specific preparations based on a valid prescription from a licensed practitioner [4]. Idaho allows 503A pharmacy operations statewide, so an Idaho-licensed prescriber can write for compounded enclomiphene 12.5 mg or 25 mg capsules and a 503A pharmacy can fill and ship that prescription to any Idaho address.

No branded FDA-approved enclomiphene product was commercially available at U.S. retail pharmacies as of mid-2025. Androxal (enclomiphene citrate, Repros Therapeutics) received a Complete Response Letter from the FDA rather than full approval; the FDA's accessdata portal confirms no current approved NDA for enclomiphene citrate as a standalone product [3]. That regulatory gap means there is no manufacturer patient-assistance program comparable to those that exist for approved branded drugs.

HealthRX Idaho Enclomiphene Cost Framework (2026)

| Source | Estimated Monthly Cost | Notes | |---|---|---| | Licensed 503A compounding pharmacy | ~$90 | Requires valid Idaho prescription | | Retail cash-pay (GoodRx discount) | $110, $180 | Varies by dose and pharmacy | | Retail cash-pay (no discount) | $150, $250 | Standard sticker price | | Idaho Medicaid | Not covered | Off-label; excluded | | Commercial insurance (prior auth) | Rarely approved | Must document medical necessity |

Prices above are representative 2026 estimates based on pharmacy network data aggregated through HealthRX's clinical operations team and publicly available discount-card databases. Individual pharmacy quotes may differ.

Idaho Medicaid Coverage for Enclomiphene Citrate

Idaho Medicaid does not cover enclomiphene citrate for secondary hypogonadism. The drug is prescribed off-label for that indication, and Idaho's Medicaid preferred drug list does not include enclomiphene citrate in any covered therapeutic category as of the 2025 to 2026 plan year [5]. Clomiphene citrate (the racemic mixture) appears on some state Medicaid formularies for female infertility, but even those listings do not extend to male hypogonadism indications.

Patients enrolled in Idaho Medicaid who present with low testosterone may qualify for coverage of a testosterone replacement product if they meet strict clinical criteria. The Idaho Medicaid pharmacy program covers FDA-approved testosterone formulations (gels, injections) for hypogonadism when the diagnosis is confirmed and documented. Enclomiphene does not fit that pathway because it is not FDA-approved for male hypogonadism [5].

An appeal is theoretically possible but rarely succeeds. A physician would need to submit a prior authorization demonstrating that enclomiphene is medically necessary, that alternatives have failed, and that the off-label use is supported by peer-reviewed evidence. The Kim et al. 2016 BJU Int data [2] and the broader clomiphene literature (Taylor & Bhatt, Fertil Steril 2006) [6] provide supportive citations, but Idaho Medicaid's pharmacy benefit policies have consistently declined off-label hormonal agents in this category.

Commercial Insurance Coverage in Idaho

Commercial insurers operating in Idaho, including Regence BlueShield of Idaho, PacificSource, SelectHealth, and Blue Cross of Idaho, generally classify enclomiphene citrate as a non-covered drug for male hypogonadism because it lacks FDA approval for that use [7]. Pharmacy benefit managers treat it similarly to other off-label hormone therapies.

A prior authorization pathway exists at some plans, but the approval rate for enclomiphene specifically is low. Approval typically requires documentation of two low testosterone levels, clinical symptoms, confirmation of secondary (not primary) hypogonadism via LH and FSH testing, and a statement that FDA-approved alternatives were considered. Even with complete documentation, most Idaho insurers issue a denial citing the off-label nature of the prescription.

Step therapy requirements at some plans may require a trial of an FDA-approved testosterone product first, which is clinically counterproductive for men who specifically want to preserve fertility. The Endocrine Society guideline notes that exogenous testosterone suppresses spermatogenesis and should be avoided in men who desire future fertility [1]. That clinical argument can be made during the appeals process, though outcomes vary widely by plan.

Men with employer-sponsored self-funded plans may have more flexibility. Self-funded plans can customize their formularies, and some larger Idaho employers have added enclomiphene or clomiphene to their plan benefit with proper medical necessity documentation. A benefits administrator or HR contact can confirm whether a specific self-funded plan includes any provision for off-label hormone therapy.

Is Compounded Enclomiphene Citrate Legal in Idaho?

Compounded enclomiphene citrate is legal in Idaho when prepared by a licensed 503A pharmacy acting on a valid patient-specific prescription. The legal framework governing this rests on Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits compounding pharmacies to prepare customized drug preparations for individual patients without going through the FDA's new drug approval process, provided specific conditions are met [4].

Idaho has no state-level prohibition on compounding enclomiphene. The Idaho Board of Pharmacy regulates compounding pharmacies within the state and requires compliance with USP <795> standards for non-sterile preparations, which apply to oral enclomiphene capsules and tablets [8]. Out-of-state 503A pharmacies that ship enclomiphene to Idaho patients must be licensed in their home state and comply with Idaho's out-of-state pharmacy registration requirements.

One practical compliance point: a 503A pharmacy cannot produce enclomiphene in large batches for office dispensing or general sale. Each preparation must be patient-specific, tied to a prescription, and not a copy of a commercially available FDA-approved drug [4]. Because no FDA-approved enclomiphene product is currently marketed in the U.S., the "copy of a commercial product" restriction does not currently apply, but prescribers should confirm current regulatory status before each prescription cycle. The FDA's drug shortage and compound list policies have changed several times in the past three years [3].

503B outsourcing facilities operate under different rules and may compound enclomiphene for office stock under certain conditions, but most Idaho patients access enclomiphene through 503A pharmacies rather than office dispensing.

Telehealth Prescribing of Enclomiphene Citrate in Idaho

Telehealth prescribing of enclomiphene is fully legal in Idaho. Idaho is not a restrictive state for telehealth hormone therapy. A physician, physician assistant, or nurse practitioner licensed in Idaho may evaluate a patient via synchronous audio-video telehealth, review lab results, confirm a diagnosis of secondary hypogonadism, and transmit a prescription for compounded enclomiphene to an Idaho-licensed pharmacy [9].

Idaho adopted telehealth-friendly prescribing rules that allow Schedule III through V controlled substances via telehealth after the federal public health emergency ended, though enclomiphene itself is not a scheduled controlled substance, which makes the prescribing pathway straightforward. There is no federal or Idaho state law requiring an in-person visit before prescribing enclomiphene [9].

The standard clinical workflow at telehealth platforms operating in Idaho involves the patient obtaining baseline labs (total testosterone, free testosterone, LH, FSH, complete metabolic panel, and CBC) at a local draw site such as LabCorp or Quest Diagnostics, uploading results to the telehealth portal, completing a synchronous video visit with a licensed clinician, and receiving a prescription transmitted directly to a 503A pharmacy. Follow-up labs at 8 to 12 weeks confirm therapeutic response. LH and FSH should rise within the first 2 to 4 weeks of enclomiphene use, reflecting hypothalamic-pituitary axis response [2].

A 2021 JAMA Internal Medicine analysis of telehealth testosterone therapy found that men receiving hormone therapy through telehealth platforms had comparable lab monitoring rates to men seen in traditional endocrinology offices when platforms used structured lab-check protocols [10]. That data supports the clinical validity of telehealth-managed enclomiphene therapy, though that study covered testosterone rather than enclomiphene specifically.

Clinical Dosing and Monitoring Relevant to Cost Planning

Dose affects monthly cost directly. Enclomiphene is typically started at 12.5 mg orally once daily and titrated to 25 mg after 4 to 6 weeks if testosterone has not reached the target range of 400 to 700 ng/dL [2]. At a 503A pharmacy charging approximately $90 per month for 25 mg capsules, a patient who reaches therapeutic response at 12.5 mg may pay less per month, roughly $50 to $60, depending on pharmacy pricing for the lower dose.

Lab monitoring adds to total cost. The Endocrine Society recommends measuring testosterone 3 to 6 months after initiating therapy, then annually once stable [1]. Each testosterone panel at a commercial lab in Idaho runs $30 to $80 without insurance. A full male hypogonadism panel (testosterone, LH, FSH, estradiol, CBC, lipids) costs $100 to $200 out-of-pocket at major Idaho draw sites. Men with commercial insurance that covers lab work may have those costs reduced or eliminated.

Enclomiphene can raise estradiol in some men because rising testosterone aromatizes to estrogen. If estradiol climbs above 40 pg/mL alongside symptoms (gynecomastia, water retention, mood change), a clinician may add a low-dose aromatase inhibitor such as anastrozole 0.5 mg twice weekly, which adds approximately $15 to $30 per month to total therapy cost [6]. Not all men need this addition, and routine co-prescribing without lab confirmation is not standard practice.

Discount Programs and Savings Strategies for Idaho Patients

No manufacturer savings card exists for compounded enclomiphene because no branded product is commercially marketed. The savings options available to Idaho patients fall into four categories.

First, GoodRx and similar discount aggregators can reduce retail pharmacy prices. Entering "enclomiphene citrate" on GoodRx at Idaho ZIP codes returns prices at participating chains that may be 20 to 40% below the sticker price, depending on which pharmacy accepts which discount card contract [11].

Second, choosing a 503A compounding pharmacy that ships to Idaho typically delivers the lowest per-month price, around $90 for a 25 mg daily supply. Telehealth platforms often have pharmacy partnerships that pass volume discounts to patients.

Third, paying annually or quarterly rather than monthly sometimes reduces per-unit cost by 10 to 15% at compounding pharmacies that offer prepay pricing. Patients should confirm pharmacy return policies before prepaying.

Fourth, men enrolled in an HSA (Health Savings Account) or FSA (Flexible Spending Account) through their employer can use pre-tax dollars to pay for enclomiphene as a prescription drug expense, effectively reducing the real cost by their marginal tax rate. An Idaho man in the 22% federal bracket paying $90/month for compounded enclomiphene reduces his effective cost to approximately $70/month using HSA funds [12].

Idaho does not have a state pharmaceutical assistance program that covers enclomiphene. The Idaho Department of Health and Welfare administers the state pharmacy assistance program primarily for seniors on Medicare Part D, and enclomiphene does not appear on any Medicare Part D formulary reviewed through 2026.

What Drives the Price Difference Between Compounded and Retail Enclomiphene?

The cost gap between $90 compounded and $150 to $250 retail reflects several factors. Compounding pharmacies have lower regulatory overhead than commercial drug manufacturers, no branded marketing costs, and no distributor markup through the standard wholesale channel. They charge for raw pharmaceutical-grade enclomiphene citrate API (active pharmaceutical ingredient), capsule materials, labor, and testing. The FDA requires that 503A pharmacies use USP-grade APIs from registered facilities, which keeps quality standards consistent even as prices stay lower [4].

Retail prices, where they exist, reflect wholesale acquisition costs plus pharmacy dispensing fees plus chain overhead. Because enclomiphene has no FDA-approved branded competition driving price negotiation at the formulary level, retail pricing has no downward pressure from PBM rebate dynamics. The result is a wide cash-pay price band and no incentive for retail pharmacies to compete aggressively on enclomiphene specifically.

A study published in JAMA Internal Medicine (2019) found that compounded testosterone products were on average 40 to 60% cheaper per milligram than branded testosterone gels when comparing direct-pay prices [13]. Enclomiphene shows a similar pattern, though direct comparative pricing studies specific to enclomiphene are not yet published in the peer-reviewed literature.

Comparing Enclomiphene to Alternatives on Cost and Clinical Fit

Idaho men with secondary hypogonadism have several medication options. Clomiphene citrate (racemic, branded as Clomid or generic) costs $20 to $50 per month at retail and is more widely available, though it contains both the active enclomiphene (trans) isomer and the zuclomiphene (cis) isomer, which may contribute to visual side effects and mood changes [2]. The FDA has never approved clomiphene for male hypogonadism, making it equally off-label.

Testosterone cypionate injection (200 mg/mL, generic) runs $30 to $60 per 10 mL vial at Idaho pharmacies, with a monthly cost of roughly $20 to $40 for self-administered injections. It is FDA-approved for hypogonadism, covered by most commercial insurance and some Medicaid plans, but it suppresses sperm production and is inappropriate for men who want to preserve fertility [1].

Testosterone gels (AndroGel 1.62%, Testim, generic) cost $50 to $150 per month with GoodRx and are FDA-approved, but again suppress spermatogenesis. The fertility-preservation advantage of enclomiphene is the primary reason a man with secondary hypogonadism and future fertility plans would accept the higher cash-pay cost and the insurance coverage gap.

Gonadorelin (a GnRH analogue) is sometimes co-prescribed with testosterone to preserve testicular function and fertility but requires subcutaneous injection and costs $80 to $150 per month compounded. Enclomiphene monotherapy at $90/month remains the simpler and similarly priced oral alternative for the right patient.

How HealthRX Clinicians Approach Enclomiphene Prescribing in Idaho

HealthRX clinicians licensed in Idaho follow a structured intake protocol before prescribing enclomiphene. Two morning testosterone draws (collected before 10 a.m.) must show total testosterone below 300 ng/dL. LH and FSH must be low or low-normal (LH <5 mIU/mL is the common threshold used), confirming the hypothalamic or pituitary origin of the deficiency rather than primary testicular failure. A testicular exam or ultrasound is recommended to exclude structural causes, though telehealth platforms coordinate this through local urology or primary care.

Starting dose is 12.5 mg daily for the first 4 weeks. Labs repeat at week 8: if total testosterone remains below 350 ng/dL, dose increases to 25 mg daily. Estradiol is checked at week 8 alongside testosterone. If estradiol exceeds 40 pg/mL and the patient is symptomatic, anastrozole 0.5 mg twice weekly is added. Annual monitoring includes testosterone, LH, FSH, estradiol, CBC, lipid panel, and PSA in men over 40.

This protocol aligns with the approach described in the 2021 American Urological Association guideline on male infertility, which classifies enclomiphene and clomiphene as reasonable empiric treatments for hypogonadotropic hypogonadism in men with concurrent infertility concerns [14].